Navigation Links
Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
Date:4/27/2009

GOTHENBURG, Sweden, April 27 /PRNewswire/ -- Cellectricon, a leading provider of automated screening solutions for drug discovery, today announced its collaboration with BioFocus DPI, a contract research organization with leading expertise in ion channel screening. BioFocus DPI will utilize Cellectricon's Dynaflow(R)HT, a fully automated patch clamp (APC) system, to further increase its electrophysiology-based screening capacity, particularly for fast ligand-gated ion channels.

"Cellectricon's unique high throughput microfluidic screening platform allows us to further develop our leading platform for ion channel screening. This collaboration gives us the opportunity to increase the throughput we provide for customers as well as the number of ion channel subtypes we can screen in an electrophysiology-based format," said Dr. Kate Hilyard, VP Biological Sciences, BioFocus DPI.

"Cellectricon is very pleased to provide BioFocus DPI with this state-of-the-art enabling technology that enhances their ion channel drug discovery offering," said Jonas Ohlsson, CEO at Cellectricon. "BioFocus DPI is a leading service provider in this field, so it is natural that we collaborate on this new high throughput ion channel screening system. We are delighted to join forces with BioFocus DPI to bring this next generation APC system - with unmatched throughput and data quality at a competitive cost - to the market."

About Dynaflow(R)HT System

The Dynaflow(R)HT microfluidic ion channel screening platform is the world's first APC technology enabling high throughput screening of all kinds of ion channels - voltage gated or ligand gated. Fully automated, the Dynaflow(R)HT has a throughput exceeding all existing APC systems - at a very competitive running cost. Rapid compound exchange enables highly complex perfusion protocols, gives superior data quality, and reduces compound usage. The new Dynaflow(R)HT screening platform is developed in close collaboration with leaders in the pharmaceutical industry.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

   http://www.cellectricon.com

    Contact details

    Jonas Ohlsson, CEO,
    Phone: +46(0)709-73-47-92, E-mail: jonas.ohlsson@cellectricon.com.

    Susanne Fagerlund, VP Marketing & Communications,
    Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com.



'/>"/>
SOURCE Cellectricon AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. KGI Names Kerry Howell Vice President for Advancement
7. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
8. Advanced Cell Technology Announces Proposed Financing
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the ... Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , bioLytical ... (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy representatives in ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the ... President of Medical Affairs.  Dr. Coleman will ... the company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers ... genetic sequencing data and clinical decision support, from quality control ... , ...
(Date:11/30/2016)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... announce the formation of EyGen, Ltd. a new ... through proof of concept. EyGen,s lead asset is ... Limited and being developed for topical ophthalmic delivery ... diseases. This agent has the potential to become ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
Breaking Biology News(10 mins):